Copyright © 2014 Elisa Verrua et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as curedmight present postglucoseGHnadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean f...
Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion fr...
Purpose: A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has be...
textabstractObjective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on...
Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likel...
Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likel...
Objective: The aim was to evaluate the validity of current remission criteria in acromegaly, a rando...
Criteria to define remission of acromegaly have changed over years. Since 2000, criteria for cure ar...
Gedik, Vedia/0000-0003-0685-2020;WOS: 000221195000009PubMed: 15080775Objective: The aim was to evalu...
Objective: Some authors proposed to lower the present postglucose GH nadir cut-off (i.e. 0.26 μg/l ...
Purpose: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituitary adenoma. GH and...
OBJECTIVE: It is still unknown whether prolonged treatment with somatostatin analogs (SSTa) may caus...
peer reviewed[en] PURPOSE: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituita...
The Author(s) 2013. This article is published with open access at Springerlink.com Aims The current ...
OBJECTIVE: Radiotherapy (RT) for pituitary adenomas, including GH-secreting ones, frequently leads t...
Criteria to define the biochemical remission of acromegaly following surgery have changed over the y...
Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion fr...
Purpose: A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has be...
textabstractObjective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on...
Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likel...
Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likel...
Objective: The aim was to evaluate the validity of current remission criteria in acromegaly, a rando...
Criteria to define remission of acromegaly have changed over years. Since 2000, criteria for cure ar...
Gedik, Vedia/0000-0003-0685-2020;WOS: 000221195000009PubMed: 15080775Objective: The aim was to evalu...
Objective: Some authors proposed to lower the present postglucose GH nadir cut-off (i.e. 0.26 μg/l ...
Purpose: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituitary adenoma. GH and...
OBJECTIVE: It is still unknown whether prolonged treatment with somatostatin analogs (SSTa) may caus...
peer reviewed[en] PURPOSE: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituita...
The Author(s) 2013. This article is published with open access at Springerlink.com Aims The current ...
OBJECTIVE: Radiotherapy (RT) for pituitary adenomas, including GH-secreting ones, frequently leads t...
Criteria to define the biochemical remission of acromegaly following surgery have changed over the y...
Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion fr...
Purpose: A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has be...
textabstractObjective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on...